Literature DB >> 34918073

Novel Functional, Health, and Genetic Determinants of Cognitive Terminal Decline: Kuakini Honolulu Heart Program/Honolulu-Asia Aging Study.

Jennifer A Margrett1, Thomas Schofield1, Peter Martin1, Leonard W Poon2, Kamal Masaki3,4, Timothy A Donlon3,4, Kalpana J Kallianpur4,5, Bradley J Willcox3,4.   

Abstract

To investigate interindividual differences in cognitive terminal decline and identify determinants including functional, health, and genetic risk and protective factors, data from the Honolulu Heart Program/Honolulu-Asia Aging Study, a prospective cohort study of Japanese American men, were analyzed. The sample was recruited in 1965-1968 (ages 45-68 years). Longitudinal performance of cognitive abilities and mortality status were assessed from Exam 4 (1991-1993) through June 2014. Latent class analysis revealed 2 groups: maintainers retained relatively high levels of cognitive functioning until death and decliners demonstrated significant cognitive waning several years prior to death. Maintainers were more likely to have greater education, diagnosed coronary heart disease, and presence of the apolipoprotein E (APOE) ε2 allele and FOXO3 G allele (SNP rs2802292). Decliners were more likely to be older and have prior stroke, Parkinson's disease, dementia, and greater depressive symptoms at Exam 4, and the APOE ε4 allele. Findings support terminal decline using distance to death as the basis for modeling change. Significant differences were observed between maintainers and decliners 15 years prior to death, a finding much earlier compared to the majority of previous investigations.
© The Author(s) 2021. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  APOE; Cognitive decline; FOXO3; Genetics; Resilience

Mesh:

Substances:

Year:  2022        PMID: 34918073      PMCID: PMC9373950          DOI: 10.1093/gerona/glab327

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.591


  48 in total

1.  The FOXO3A rs2802292 G-allele associates with improved peripheral and hepatic insulin sensitivity and increased skeletal muscle-FOXO3A mRNA expression in twins.

Authors:  Karina Banasik; Rasmus Ribel-Madsen; Anette P Gjesing; Lise Wegner; Asa Andersson; Pernille Poulsen; Anders Borglykke; Daniel R Witte; Oluf Pedersen; Torben Hansen; Allan Vaag
Journal:  J Clin Endocrinol Metab       Date:  2010-09-29       Impact factor: 5.958

Review 2.  Mitochondria and FOXO3 in stem cell homeostasis, a window into hematopoietic stem cell fate determination.

Authors:  Raymond Liang; Saghi Ghaffari
Journal:  J Bioenerg Biomembr       Date:  2017-06-21       Impact factor: 2.945

Review 3.  Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment.

Authors:  Per Svenningsson; Eric Westman; Clive Ballard; Dag Aarsland
Journal:  Lancet Neurol       Date:  2012-08       Impact factor: 44.182

4.  FoxO3 coordinates metabolic pathways to maintain redox balance in neural stem cells.

Authors:  Hyeonju Yeo; Costas A Lyssiotis; Yuqing Zhang; Haoqiang Ying; John M Asara; Lewis C Cantley; Ji-Hye Paik
Journal:  EMBO J       Date:  2013-09-06       Impact factor: 11.598

Review 5.  Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms.

Authors:  Laure Rouch; Philippe Cestac; Olivier Hanon; Charlène Cool; Catherine Helmer; Béatrice Bouhanick; Bernard Chamontin; Jean-Franҫois Dartigues; Bruno Vellas; Sandrine Andrieu
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

6.  Terminal cognitive decline: accelerated loss of cognition in the last years of life.

Authors:  Robert S Wilson; Todd L Beck; Julia L Bienias; David A Bennett
Journal:  Psychosom Med       Date:  2007-02-07       Impact factor: 4.312

Review 7.  Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.

Authors:  Philip B Gorelick; Angelo Scuteri; Sandra E Black; Charles Decarli; Steven M Greenberg; Costantino Iadecola; Lenore J Launer; Stephane Laurent; Oscar L Lopez; David Nyenhuis; Ronald C Petersen; Julie A Schneider; Christophe Tzourio; Donna K Arnett; David A Bennett; Helena C Chui; Randall T Higashida; Ruth Lindquist; Peter M Nilsson; Gustavo C Roman; Frank W Sellke; Sudha Seshadri
Journal:  Stroke       Date:  2011-07-21       Impact factor: 7.914

8.  Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease.

Authors:  Patricia Spilman; Natalia Podlutskaya; Matthew J Hart; Jayanta Debnath; Olivia Gorostiza; Dale Bredesen; Arlan Richardson; Randy Strong; Veronica Galvan
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

9.  The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment.

Authors:  Ihab Hajjar; Jeannie Schumpert; Victor Hirth; Darryl Wieland; G Paul Eleazer
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2002-07       Impact factor: 6.053

10.  Intraindividual variability across cognitive domains: investigation of dispersion levels and performance profiles in older adults.

Authors:  Jennifer V Hilborn; Esther Strauss; David F Hultsch; Michael A Hunter
Journal:  J Clin Exp Neuropsychol       Date:  2009-05       Impact factor: 2.475

View more
  1 in total

1.  FOXO3, a Resilience Gene: Impact on Lifespan, Healthspan, and Deathspan.

Authors:  Timothy A Donlon; Brian J Morris; Kamal H Masaki; Randi Chen; Phillip M C Davy; Kalpana J Kallianpur; Kazuma Nakagawa; Jesse B Owens; D Craig Willcox; Richard C Allsopp; Bradley J Willcox
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2022-08-12       Impact factor: 6.591

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.